Caissa Capital Management ltd. - 15 Jun 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
10%+ Owner
Signature
Cambyz Golestaneh, Title: Director
Issuer symbol
AVTX
Transactions as of
15 Jun 2023
Net transactions value
+$31,644
Form type
4
Filing time
20 Jun 2023, 16:04:50 UTC
Previous filing
14 Jun 2023
Next filing
27 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Purchase $11,640 +3,160 +0.22% $3.68* 1,420,700 15 Jun 2023 See Footnote (1) F1, F2
transaction AVTX Common Stock Purchase $11,714 +3,000 +0.21% $3.90* 1,423,700 16 Jun 2023 See Footnote (1) F1, F3
transaction AVTX Common Stock Purchase $8,289 +2,000 +0.14% $4.14* 1,425,700 20 Jun 2023 See Footnote (1) F1, F4
holding AVTX Common Stock 182,300 15 Jun 2023 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.19 to $3.99, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.745 to $3.98, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.07 to $4.17, inclusive.
F5 These shares are directly owned by Mr. Golestaneh in his personal capacity.